ArticleJournal of molecular medicine (Berlin, Germany)2018
Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.
Article in Journal of molecular medicine (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Towards an Original Anti-ASFV Vaccine: Cellular Immunity Induced by Extracellular Vesicles Engineered with ASFV Proteins.Vaccines · 2026Article
- Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms.Small science · 2025Review
- Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies.Signal transduction and targeted therapy · 2025Review
- Extracellular vesicle-based anti-HOXB7 CD8Cancer gene therapy · 2024Article
- Tumor immune escape: extracellular vesicles roles and therapeutics application.Cell communication and signaling : CCS · 2024Review
- Article
- Engineered exosomes from different sources for cancer-targeted therapy.Signal transduction and targeted therapy · 2023Review
- Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein.Vaccines · 2022Article
- Strong SARS-CoV-2 N-Specific CD8Viruses · 2022Article
- Extracellular Vesicles and Their Use as Vehicles of Immunogens.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Small extracellular vesicles in cancer.Bioactive materials · 2021Review
- Virus-Induced CD8Vaccines · 2021Article
- Long-Term Antitumor CD8Cancers · 2021Article
- The C-Terminal Domain of NefVaccines · 2021Article
- Simultaneous CD8Vaccines · 2021Article
- Influenza virus neuraminidase regulates host CD8Communications biology · 2020Article
- N-Terminal Fatty Acids of NEFVaccines · 2020Article
- Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson's Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study.International journal of molecular sciences · 2019Article
- Mitochondrial Dysfunction and Aging: Insights from the Analysis of Extracellular Vesicles.International journal of molecular sciences · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
We recently described a novel biotechnological platform for the production of unrestricted cytotoxic T lymphocyte (CTL) vaccines. It relies on in vivo engineering of exosomes, i.e., nanovesicles constitutively released by all cells, with full-length antigens of choice upon fusion with an exosome-anchoring protein referred to as Nef KEY MESSAGES: We established a novel, exosome-based method to produce unrestricted CTL vaccines. This strategy is effective in breaking the tolerance towards tumor self-antigens. Our method is also useful to elicit antigen-specific CTL immunity in humans. These findings open the way towards the use of this antitumor strategy in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.